Randomized phase III study comparing an early PET driven treatment deescalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.

被引：7
|
作者：
Casasnovas, Olivier
Brice, Pauline
Bouabdallah, Reda
Salles, Gilles A.
Stamatoulas, Aspasia
Dupuis, Jehan
Reman, Oumedaly
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Kamal
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Delarue, Richard
Berriolo-Riedinger, Alina
Edeline, Veronique
Traverse-Glehen, Alexandra
Andre, Marc
Mounier, Nicolas
Meignan, Michel
机构：
[1] CHU Bocage, Serv Hematol Clin, Dijon, France
[2] Paris Diderot Sorbonne Univ, St Louis Hosp, AP HP, Paris, France
[3] Inst Paoli Calmettes, Marseille, France
[4] Ctr Hosp, Serv Hematol, Lyon, France
[5] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[6] CHU Henri Mondor, Dept Hematol, Creteil, France
[7] Ctr Hosp Univ Caen, Dept Hematol, Caen, France
[8] CHU Nantes, Dept Hematol, Nantes, France
[9] Ctr Hosp Sud Francilien, Corbeil Essonnes, France
[10] Univ Hosp Bordeaux, Dept Haematol, Bordeaux, France
[11] Ctr Leon Berard, Dept Hematol, Lyon, France
[12] CHU Nancy, Dept Hematol, Nancy, France
[13] Ctr Hosp Reg Univ CHRU Lille, Dept Clin Hematol, Lille, France
[14] Univ Lille 2, Unite Grp Rech Formes Injetables & Technol Associ, Lille, France
[15] Hop Necker Enfants Malad, Dept Hematol, Paris, France
[16] Ctr Georges Francois Leclerc, Dept Nucl Med, Dijon, France
[17] Inst Curie, Paris, France
[18] Hosp Civils Lyon Hop Lyon Sud, Pierre Benite, France
[19] Catholic Univ Louvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium
[20] CHU Archet, Dept Hematol, Nice, France
[21] Hop Henri Mondor, LYSA IM, Creteil, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.7503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7503
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study
    Borchmann, Peter
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Haverkamp, Heinz
    Kreissl, Stefanie
    Fuchs, Michael
    Soekler, Martin
    Hellmuth, Johannes C.
    Meissner, Julia
    Mathas, Stephan
    Behringer, Karolin
    Dietlein, Markus
    Kobe, Carsten
    Diehl, Volker
    Engert, Andreas
    BLOOD, 2015, 126 (23)
  • [22] Positron Emission Tomography- (PET) guided Treatment in early-Stage Hodgkin Lymphoma with favorable Risk Factors: Final Results of the international randomized Phase III HD16 Trial conducted by the German Hodgkin Study Group
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (04) : 414 - 415
  • [23] Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.
    Borchmann, Peter
    Haverkamp, Heinz
    Lohri, Andreas
    Kreissl, Stefanie
    Greil, Richard
    Markova, Jana
    Feuring-Buske, Michaela
    Meissner, Julia
    Duehrsen, Ulrich
    Engel, Nicole
    Keller, Ulrich
    Maschmeyer, Georg
    Dietlein, Markus
    Kobe, Carsten
    Fuchs, Michael
    Diehl, Volker
    Engert, Andreas
    BLOOD, 2014, 124 (21)
  • [24] Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study
    Borchmann, Peter
    Goergen, Helen
    Kobe, Carsten
    Lohri, Andreas
    Greil, Richard
    Eichenauer, Dennis A.
    Zijlstra, Josee M.
    Markova, Jana
    Meissner, Julia
    Feuring-Buske, Michaela
    Huttmann, Andreas
    Dierlamm, Judith
    Sokler, Martin
    Krause, Stefan W.
    Eich, Hans
    Baues, Christian
    Kreissl, Stefanie
    Fuchs, Michael
    Dietlein, Markus
    Engert, Andreas
    BLOOD, 2017, 130
  • [25] Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
    Justin Ferdinandus
    Lutz van Heek
    Katrin Roth
    Markus Dietlein
    Hans-Theodor Eich
    Christian Baues
    Peter Borchmann
    Carsten Kobe
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 490 - 495
  • [26] Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
    Ferdinandus, Justin
    van Heek, Lutz
    Roth, Katrin
    Dietlein, Markus
    Eich, Hans-Theodor
    Baues, Christian
    Borchmann, Peter
    Kobe, Carsten
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (02) : 490 - 495
  • [27] Final Analysis of a Randomized Phase II Study With Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Patients With Early Unfavorable Hodgkin Lymphoma-PVAG-14 Pilot
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 14 - 15
  • [28] PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
    Borchmann, Peter
    Goergen, Helen
    Kobe, Carsten
    Lohri, Andreas
    Greil, Richard
    Eichenauer, Dennis A.
    Zijlstra, Josee M.
    Markova, Jana
    Meissner, Julia
    Feuring-Buske, Michaela
    Huttmann, Andreas
    Dierlamm, Judith
    Soekler, Martin
    Beck, Hans-Joachim
    Willenbacher, Wolfgang
    Ludwig, Wolf-Dieter
    Pabst, Thomas
    Topp, Max S.
    Hitz, Felicitas
    Bentz, Martin
    Keller, Ulrich Bernd
    Kuhnhardt, Dagmar
    Ostermann, Helmut
    Schmitz, Norbert
    Hertenstein, Bernd
    Aulitzky, Walter
    Maschmeyer, Georg
    Vieler, Tom
    Eich, Hans
    Baues, Christian
    Stein, Harald
    Fuchs, Michael
    Kuhnert, Georg
    Diehl, Volker
    Dietlein, Markus
    Engert, Andreas
    LANCET, 2017, 390 (10114): : 2790 - 2802
  • [29] FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-
    Fuchs, M.
    Wongso, D.
    Pluetschow, A.
    Feuring-Buske, M.
    Hertenstein, B.
    Hoeffkes, H. G.
    Vogelhuber, M.
    von Tresckow, B.
    Biersack, H.
    Link, H.
    Topp, M. S.
    Fischer, N.
    Bredenfeld, H.
    Sasse, S.
    Behringer, K.
    Boell, B.
    Borchmann, P.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 497 - 497
  • [30] Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized phase III intergroup study in 381 patients.
    Hagenbeek, A
    Eghbali, H
    Monfardini, S
    Resegotti, E
    Hoskin, J
    de Wolf-Peeters, C
    McLennan, K
    Staab-Renner, E
    Schott, A
    Teodorovic, I
    Negrouk, A
    van Glabbeke, M
    Marcus, R
    BLOOD, 2001, 98 (11) : 843A - 843A
12345